Sejong Medical Acquires 14% Stake in Genencell for 'Health Functional Food R&D'
[Asia Economy Reporter Lee Seon-ae] Sejong Medical announced on the 20th that it acquired 14.01% (660,000 shares) of Genencell, which is engaged in the research and development of pharmaceuticals, cosmetics, and health functional foods, for 6,289.8 million KRW. This accounts for 14.5% of its equity capital, and the counterparty of the transaction is Kang Se-chan, the largest shareholder of Genencell. The purpose of the equity acquisition is business diversification.
Hot Picks Today
"Quit Job to Start Life in Canada, Now Forced to Return Home"… Language School Closure Leaves Korean Students Stranded
- [Exclusive] "Oh, Oh! Why Is the Seatback Like This?" Hyundai Ioniq 9 Recalled in Korea: 15,000 Units Due to Power Seat Entrapment Risk
- If AI Music Cannot Be Stopped, Bring It Into the System... Debate Over 'Human Creativity' Standards
- "After Spending 170,000 Won on Hanwoo, This Is What I Got": Why Webtoon Artist Kim Gyusam Decided to Give Cash Instead
- "It's Neither Rome Nor Florence"...The Italian Attractions Korean Travelers Are Flocking to With 300% Sales Growth
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
